People have been studying steroid hormones for decades, long before molecular biology turned into a household name. 11Α,17Α Dihydroxy-Progesterone became a point of focus as research moved to synthetic corticosteroids in the mid-20th century. Scientists, working with natural extracts, learned how to tweak base molecules to deliver new effects. From digging in the medical libraries, I learned that the interest in such derivatives grew from a hunt to manage inflammation and hormonal imbalances better than classical forms allowed. Early breakthroughs happened in academic labs, eventually spilling over to big pharmaceutical players as patents heated up and clinical curiosity grew. This quest still drives pharmaceutical chemistry forward.
11Α,17Α Dihydroxy-Progesterone sits among important intermediates for corticosteroids synthesis. Unlike basic steroid precursors, it brings a pattern of hydroxylation that lets chemists move in several pathways for tailoring end-products. Grab a reference sample, and its powdery consistency stands out. In supply chains, this compound isn’t something you pick up like a retail supplement; it waits behind regulatory checks and controlled distribution channels, mostly funneling toward other syntheses rather than direct consumer use.
In hands-on use, you spot a white or off-white crystalline form. The melting point tells you a lot, usually falling between 215 and 225°C, helping verify purity at a glance. Its solubility frustrates many: water barely nudges it, but most organic solvents like chloroform, dioxane, and ethanol bring it into solution, handy for lab workflows and extraction. Chemically, the dual hydroxyl groups at 11α and 17α chromium spots change its hydrogen-bonding networks when working out reactions on the bench. That’s a detail I’ve seen frustrate new PhDs trying to predict chromatography runs.
Lab suppliers put technical purity at or above 98%—any less and batch-to-batch results start drifting. Proper labeling never gets skipped, especially under current regulations and audit requirements. Each container usually lists the exact batch, manufacturer, country of origin, and storage recommendation (refrigerator or dry shelf, often the former). Manufacturers run FTIR and NMR scans to back up purity and chemical identification, with those reports saved for six years if anyone audits the batch history. Chemical safety info rides sidecar with the product, never just buried online.
The pathway to 11Α,17Α Dihydroxy-Progesterone isn’t a walk in the park. Production flows from progesterone, going through a 11α-hydroxylation, typically using microbial methods like Rhizopus nigricans or Corynebacterium species. Old methods leaned on chemical oxidants, but those brought too many toxic byproducts and inconsistent yields. Lab-scale runs may involve protection-deprotection steps between hydroxylations to avoid unwanted side reactions. Larger plants adopted biotransformation for a good mix of yield and selectivity, borrowing tricks from green chemistry. My own hands-on stints in scale-up labs drove home the reality: even small changes in substrate concentration or pH bend the reaction curve, and cleanup isn’t trivial.
What matters most for this molecule is its flexibility. The paired hydroxyl groups on the steroid nucleus create open highways for further functionalization: you see acylation, etherification, and oxidation chemistry all drawn from these “handles.” In corticosteroid synthesis, the molecule acts not only as a stepping stone but as a way to introduce specificity at sites relevant for biological binding and metabolism. I’ve watched teams debate hours over the right sequence: add a functional group first, or swap the order and deal with side reactions? The molecule’s backbone resists some reagents but welcomes others, giving medicinal chemists powerful options—and sometimes unpredictable cleanups.
The nomenclature list reads like a glossary: 11α,17α-Dihydroxyprogesterone, 11,17-Dihydroxyprogesterone, sometimes shortened even further in catalogues. Rarely, you’ll see it referenced by developmental code numbers in old pharma files. Few commercial brand names exist, since this compound rarely hits the pharmacy shelf in pure form—its legacy rides on the derivatives and end products it helps create. Speaking from habit, chemists usually stick with the IUPAC-rooted term to dodge confusion or mislabeling in the lab. I remember one project snagged for a week just because the label used an outdated synonym.
Grounded lab work takes safety as seriously as synthesis. 11Α,17Α Dihydroxy-Progesterone doesn’t carry the immediate hazards of strong acids or bases, but inhalation of fine powders and long-term exposure to hormone-active compounds pose risks. Labs run fumehoods every time they weigh or dissolve the powder. Gloves, goggles, lab coats—these aren’t negotiable. Material Safety Data Sheets clarify safe handling, spill control, first aid, and environmental management, with everything updated according to REACH and OSHA regulations. Storage never mixes with food prep or open workspace, and disposal uses sealed, labeled containers for regulated waste pickup. In every audit I’ve sat through, safety documentation gets more scrutiny than bench notes.
The biggest footprint lands in the synthesis of other corticosteroids and glucocorticoids, like hydrocortisone and prednisolone. Hospitals and clinics rarely see this intermediate itself—the final drugs pass through clinical trials, regulatory hurdles, and decades of efficacy studies. Chemical researchers keep it in their toolkit for SAR (structure-activity relationship) studies to design drugs with better selectivity, potency, or metabolic stability. Beyond medicine, testing labs use it as an analytical standard for hormone detection in blood serum applications. Veterinary pharmaceuticals also value such intermediates in crafting steroidal anti-inflammatories, echoing human medicine trends.
Companies pour real resources into making derivatives faster, cleaner, and with fewer byproducts. R&D groups apply new microbial strains or engineered enzymes to sharpen yields and limit waste streams. Green chemistry efforts start with this class of compounds because the pharma sector faces mounting pressure to minimize hazardous solvents and energy use. I’ve sat in strategy sessions where every major firm weighed investing in new biotransformation patents versus negotiating licensing from upstart rivals. The pipeline for new corticosteroids rarely slows, and each improvement in the intermediate simplifies downstream purification and regulatory filings.
Toxicological studies on 11Α,17Α Dihydroxy-Progesterone itself lag behind those on the clinical end-products, because human exposure comes primarily at small, controlled scales. Standard genotoxicity and repeat-dose testing shape the industry’s risk management. Most findings mirror those of other steroid intermediates: chronic overexposure risks hormone disruption, with potential for reproductive, hepatic, and immune system side effects if not tightly controlled. No scientist ignores the lessons from endocrine disruptor studies—every new intermediate faces full scrutiny under international safety frameworks. For workers, chronic exposure monitoring forms a key part of occupational health programs. My personal experience is that once a year, proper medical surveillance feels worth every minute spent.
Steroid chemistry marches forward with 11Α,17Α Dihydroxy-Progesterone still at its intersection. Newer synthetic routes keep showing up in patents and technical journals, aimed at smaller environmental footprints and higher selectivity. AI-guided retrosynthesis now pulls up this intermediate in new corticosteroid discoveries that could deliver better side-effect profiles. Researchers in environmental sciences also track residues and breakdown pathways in waste streams, opening new areas for bioremediation. The next twenty years likely bring sharper focus on sustainable production, deeper toxicology, and perhaps, by some clever turn, new medical uses yet uncovered. Each chemical shift or microbial tweak along the way keeps this molecule on the short list for any team working to expand or refine steroid-based therapies.
11Α,17Α Dihydroxy-Progesterone belongs to a group of steroid hormones similar in structure to natural progesterone. It doesn’t get the spotlight much, but anyone with a background in biochemistry or medicine may have seen its name show up in textbooks or drug formulations. It’s a raw material that helps build more common medical steroids, especially those used in hormone therapy or inflammation treatment.
Labs use this compound as a stepping stone in the creation of corticosteroids and other hormones. Corticosteroids treat everything from asthma and arthritis to skin flares and immune conditions. Hydrocortisone, one of the most famous steroids, starts with compounds like 11Α,17Α Dihydroxy-Progesterone. Without these building blocks, the drug supply chain would face a challenge.
Most of these hormones can’t just come from a plant or animal in the shape doctors need. Chemists tweak the structure, add the right pieces, remove others, and adjust the potency. This middle step usually doesn’t catch anyone’s attention outside the lab, but it may decide whether someone’s inhaler or topical ointment works right.
Doctors rely on reliable medicines to control inflammation, allergies, and hormonal imbalances. That’s where the chemistry work behind the scenes gets its value. It’s easy to brush past the process and focus just on the end tablets or creams, but shortages of precursor steroids like 11Α,17Α Dihydroxy-Progesterone can slow down pharmaceutical manufacturing. I once met a pharmacy tech who mentioned how a small supply change in just one hormone could put certain medications on backorder for weeks.
Research careers also benefit from this compound. Some scientists study how changes in the structure might give a drug better absorption or fewer side effects. Others dig into its role in adrenal function and diseases like congenital adrenal hyperplasia (CAH), where these hormones build up and disrupt normal development. Even though patients rarely receive 11Α,17Α Dihydroxy-Progesterone directly, understanding its metabolic path helps doctors spot and treat rare hormonal disorders.
Not all countries have the same access to core pharmaceutical ingredients. That gap can mean fewer treatment options or higher drug prices for families. Supply chain hiccups–produced by political issues, trade restrictions, or uneven production–won’t just make life complicated for pharmaceutical companies. Patients who rely on steady medication face the greatest risks if shortages trickle into widely used drugs.
Keeping pharmaceutical manufacturing stable shouldn’t depend on just a couple of global factories. Local production, reliable sourcing, and transparency about supply can ease the strain. A few groups have started working on plant-based or fully synthetic routes so drugmakers can avoid bottlenecks. Scientists keep searching for ways to streamline the steps from these raw steroid compounds to finished medicines, cutting out unnecessary processes or making the materials safer to handle.
Whenever you pick up a steroid prescription for a rash, breathing issue, or replacement hormone therapy, remember there’s complex chemistry powering every capsule. Behind that chemistry stands a chain of steps, each shaped by compounds like 11Α,17Α Dihydroxy-Progesterone. Paying attention to this part of the process matters for drug safety, accessibility, and the future of personalized medicine.
Stepping into a pharmacy, you will often see shelves lined with different hormones and steroids. Each promises a fix—some for serious conditions, some for research. One compound, 11Α,17Α Dihydroxy-Progesterone, lands in the crowd as a synthetic hormone related to progesterone. While this chemical finds use in certain medical contexts, it comes with effects that deserve real attention.
Nobody likes to find surprises when it comes to health. Talking with doctors and reading published studies, folks find a familiar pattern with hormones like this one. People mention they feel moody, have headaches, and even notice changes in their skin such as acne or rash. This mirrors personal observations—long work at a clinic taught me how hormones unsettle the balance in the body. One patient described sudden fatigue after a few days, while another seemed fine until sleep problems kicked in after a week.
Lab and animal research reported in journals like Endocrinology back this up. They point to swelling, bloating, or weight changes. This makes sense, considering how hormones play roles in fluid retention. Just look at what happens with regular progesterone therapy—water weight adds up quickly for some.
Dry skin or a breakout isn’t where the story ends. Some side effects grow heavier. Hormones mess with more than just mood—they touch the whole body. Blood clot risk, for example, rises with many synthetic progestins. Experience shows these complications appear most often in those with risk factors like smoking or a family history of clotting problems. Hormones sometimes lead to shifts in how blood sugar works, which gets dangerous for anyone with diabetes or prediabetes. Specialist reviews have seen cases where taking similar steroids tipped the balance from controlled sugars to unmanaged spikes and crashes.
Long-term use adds other worries. Some studies, like those published by the Journal of Clinical Endocrinology, mention liver strain as a hidden cost. Rare, sure, but some sensitive people face itching, dark urine, and jaundice—a sign to call a doctor, fast. At the extreme, the immune system itself can react. Swelling in the lips or throat points to allergic response. In my own practice, fast action made all the difference for patients who noticed these signs right after starting new medication.
The tough part: there’s no perfect fix, but people can lower risk by being alert. Honest conversation with your healthcare provider comes first. Ask for blood tests before starting new hormones and again after a few weeks. Watch for small changes—feelings of anxiety, weight gain, or changes in appetite can serve as important early clues. People with a background of hormone-sensitive cancers should talk through risks in detail, because hormones might wake up old problems.
Doctors chasing safer outcomes now recommend close monitoring, especially early on. Pharmacists now check drug histories for dangerous combinations—something that wasn’t routine a decade ago. Reporting any reaction as soon as it starts helps researchers and other patients learn, so nobody walks into risk blindly.
Data from clinical studies give the hard facts, but real-world stories fill in the gaps. Families, friends, and support groups help each other notice new symptoms and share what works to manage them. Progress comes from listening, reporting problems, and sticking to a plan that puts safety first.
Anyone who’s handled pharmaceutical-grade powders has learned a hard truth: storage isn’t just technical detail, it’s a key part of safety and reliability. 11Α,17Α Dihydroxy-Progesterone might sound like a mouthful, but in practice, we’re talking about a steroid compound that chemists, researchers, and pharmacists rely on for precision. If someone lets high-quality material turn useless by storing it poorly, trust goes out the window fast. I remember a university lab back in the 2000s where mishandled hormones led to several experiments being scrapped, setting back months of work.
Most powders clump or degrade if left out on a workbench, exposed to air, light, or heat. Years working around APIs (active pharmaceutical ingredients) drove home just how quickly moisture can spoil a batch—even a few hours in a humid room can lead to a mess. 11Α,17Α Dihydroxy-Progesterone reacts in pretty much the same way. To protect both its chemical integrity and therapeutic usefulness, you store it somewhere dry and cool. Most credible suppliers recommend a range between 2°C and 8°C, inside sealed containers that keep air and moisture out. Cold storage rooms with built-in humidity controls have become standard.
Light isn’t just a problem for vampires—it knocks out sensitive molecules, too. I’ve seen pure white powders yellow after sunlight exposure. Amber glass bottles and opaque packaging cut down on UV rays, preserving potency and stopping decomposition. These small steps can extend shelf life and keep everything working as the label claims.
Too many accidents start with mislabeling. Someone grabs the wrong bottle, forgets the lot number, or leaves something out on a bench and nobody knows how long it sat there. Detailed labels—listing batch, weight, concentration, and date—help keep mistakes out of the supply chain. Each time you return a bottle to its shelf, you double-check the info. Some labs even log every entry and removal, so every milligram used stays tracked. Good habits like these prevent not only waste but legal headaches when audits roll around.
Lab benches often collect chemical dust from a dozen projects. Cross-contamination can ruin an experiment or pose real health risks. I got in the habit of storing anything sensitive on high shelves and in sealed boxes, away from acids, solvents, and especially communal fridges. Cleaning before and after every use doesn’t just please inspectors; it ensures nobody breathes in particles or stirs up a toxic cloud.
A well-run lab finds clever ways to build better habits. Some keep temperature monitors with alarm systems. Others write checklists for staff and use color-coded racks based on compound type. Training every member—down to new grads—protects the supply line. Peer-reviewed sources like the European Pharmacopoeia lay out best practices, but experience in local conditions can be just as important. In the end, storage isn’t boring; it’s about making sure what comes out of a bottle is as safe and powerful as what went in.
People often hear technical terms in the world of medicine and pharmaceuticals and feel like it’s all too complicated to care about. But certain substances—especially those that can shift the body’s hormonal balance—demand careful handling. 11Α,17Α Dihydroxy-Progesterone may sound obscure, yet this compound sits in the same family as other steroids that doctors rely on for real treatments. Whether a prescription is necessary isn’t just red tape; it links directly to patient safety, fraud prevention, and the whole structure of modern healthcare accountability.
These days, every developed country treats steroid hormones as controlled substances. Regulation didn’t arise from bureaucrats just looking for work. Abuse of steroid agents, either through bodybuilding or attempting to treat mysterious aches without seeing a real physician, has left many people with irreversible side effects. There are young adults with damaged livers and teenagers with stunted growth, because someone sold them powerful drugs without asking questions.
No over-the-counter aisle holds real prescription hormone analogues, and that’s on purpose. The FDA and similar agencies across Europe and Asia have decided that compounds like 11Α,17Α Dihydroxy-Progesterone belong on the prescription list, because a wrong dose or a sloppy drug interaction can mean serious harm. Many similar hormones can throw off menstrual cycles, spark unusual weight gain, or mess with cholesterol. Self-treatment can spiral into life-threatening events, like severe blood clots or even heart attacks.
Not all access happens through the local drugstore. A quick online search will turn up sites promising all sorts of specialty substances with no questions asked. I’ve spent time reporting on drug safety, and stories keep coming in from those duped by counterfeit pills. Lab tests on “steroids” shipped from mystery suppliers have turned up everything from heavy metals to cornstarch. Unscrupulous sellers target people desperate for shortcuts, and regulators often play whack-a-mole to shut them down. The takeaway: even if someone manages to buy 11Α,17Α Dihydroxy-Progesterone off the Internet, no safety net waits to catch them.
A real doctor’s judgment goes far beyond writing prescriptions. They track medical history, catch warning signs, and weigh risks against benefits. So, being forced to get a prescription for 11Α,17Α Dihydroxy-Progesterone isn’t just a legal speed bump—it’s basic patient protection. In countries with strong access to healthcare, most people agree that gatekeeping is better than the fallout from letting hormone drugs float unchecked.
For those who truly need medications in this class, the solution isn’t to wish away the rules, but to push for better healthcare access. More pharmacists working collaboratively with physicians, smarter digital health records, or easier telemedicine appointments could help bring needed treatments to those who qualify. But the core message stands: specialty hormones like 11Α,17Α Dihydroxy-Progesterone land squarely in prescription territory, and for good reasons—each grounded in actual harm seen when those rules get ignored.
Sorting through scientific literature and trusted medical resources, 11Α,17Α Dihydroxy-Progesterone doesn’t come up with clear dosing charts like you’d see for aspirin or metformin. This isn’t a drug sitting on pharmacy shelves or showing up in daily clinical rounds. Endocrine journals and pharmacologists highlight it as either an intermediate in steroid synthesis or as a research compound under the microscope. Human dosing, where documented, stays deeply tied to controlled studies or experimental medical use, not routine doctor’s office standards.
Doctors and pharmacists know that safety gets tricky when a drug hasn’t moved through large clinical trials or gathered a base of prescribing experience. Progesterone analogs can crank up side effects if handled wrong, especially in vulnerable populations or folks with hormone-sensitive conditions. Without a track record for things like 11Α,17Α Dihydroxy-Progesterone, medical societies and regulatory agencies haven’t published recommendations for routine use.
Trying out a drug without guidance from trial data feels like cooking without a recipe; something might turn out fine, but the risks run high. The U.S. Food and Drug Administration and agencies in Europe set clear demands for dosing studies and safety profiles. This isn’t bureaucracy dragging its feet; it’s a matter of patient safety and consistent results.
Curiosity across the medical field keeps driving new hormone analogs to be tested for rare adrenal conditions and complex reproductive syndromes. Someone might find a benefit tucked away in animal studies or early-phase clinical reports, but without dose-finding studies in humans, even the most creative physician would hesitate to move forward. Uncertainty around the right amount to give, how often to give it, and what to monitor for sits heavy on any trained clinician’s mind.
Hormone therapies deserve careful attention, especially for those facing adrenal insufficiency, rare metabolic disorders, or reproductive issues. These patients want hope, but they also deserve safety. Physicians lean on therapies that build a wall of evidence through review articles, consensus guidelines, and direct regulatory approval. For something like 11Α,17Α Dihydroxy-Progesterone, stepping outside those guardrails asks for an honest discussion about risks, transparency about what’s not known, and close, continuous monitoring—if trial use proceeds at all.
Solving this gap means funding well-designed human trials and building open communication between researchers, pharmacists, and clinicians. Medical publishers and regulatory agencies publish alert notices and guidelines to keep practitioners in the loop about new experimental findings. Professional societies can support knowledge sharing so that, when promising new therapies appear, experts collaborate instead of guessing.
Bottom Line: 11Α,17Α Dihydroxy-Progesterone isn’t part of standard patient care because safety and dosing data haven’t cleared the bench to bedside leap. Patients, researchers, and clinicians moving forward need extensive trial evidence, transparent reporting, and expert review before anyone can recommend a dosing schedule in good faith.| Names | |
| Preferred IUPAC name | (11α,17α)-11,17-Dihydroxypregn-4-ene-3,20-dione |
| Other names |
11α,17α-Dihydroxyprogesterone
11alpha,17alpha-Dihydroxyprogesterone 11α,17α-Dihydroxypregn-4-ene-3,20-dione |
| Pronunciation | /ˈɪlˌæ səvˌɛntinˌæ daɪˈhaɪdrɒksi proʊˈdʒɛstərəˌroʊn/ |
| Preferred IUPAC name | (11α,17α)-11,17-Dihydroxypregn-4-ene-3,20-dione |
| Other names |
11α,17α-Dihydroxyprogesterone
11α,17α-Dihydroxy-4-pregnene-3,20-dione |
| Pronunciation | /ˌɪlˌiːˈfæsˌɛˈntiːnˌdaɪhaɪˈdrɒksi-proʊˈʤɛstərəˌroʊn/ |
| Identifiers | |
| CAS Number | '979-02-2' |
| Beilstein Reference | 3538699 |
| ChEBI | CHEBI:34581 |
| ChEMBL | CHEMBL493671 |
| ChemSpider | 51988410 |
| DrugBank | DB01363 |
| ECHA InfoCard | 100.036.232 |
| EC Number | 3.1.7.3 |
| Gmelin Reference | 126313 |
| KEGG | C15294 |
| MeSH | D006627 |
| PubChem CID | 11524712 |
| RTECS number | RY3225000 |
| UNII | K848JZ4886 |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID8022514 |
| CAS Number | 604-09-1 |
| Beilstein Reference | 1304093 |
| ChEBI | CHEBI:76235 |
| ChEMBL | CHEMBL15976 |
| ChemSpider | 11862472 |
| DrugBank | DB01481 |
| ECHA InfoCard | 03e223e2-c837-44b3-8eaa-7ad064e9b697 |
| EC Number | 1.1.1.51 |
| Gmelin Reference | 74644 |
| KEGG | C14351 |
| MeSH | D009974 |
| PubChem CID | 123709 |
| RTECS number | JR2450000 |
| UNII | UN6J3435C7 |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID4045042 |
| Properties | |
| Chemical formula | C21H30O4 |
| Molar mass | 386.512 g/mol |
| Appearance | White to off-white crystalline powder |
| Odor | Odorless |
| Density | 1.2 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | 2.09 |
| Acidity (pKa) | 12.59 |
| Basicity (pKb) | 3.82 |
| Magnetic susceptibility (χ) | -1022.0e-6 cm^3/mol |
| Refractive index (nD) | 1.5840 |
| Viscosity | Viscous oil |
| Dipole moment | 3.09 D |
| Chemical formula | C21H30O4 |
| Molar mass | 330.461 g/mol |
| Appearance | White to Off-White Solid |
| Odor | Odorless |
| Density | 1.17 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 2.01 |
| Vapor pressure | 2.27E-10 mmHg |
| Acidity (pKa) | 14.88 |
| Basicity (pKb) | 13.09 |
| Magnetic susceptibility (χ) | -98.7×10⁻⁶ cm³/mol |
| Viscosity | Viscous oil |
| Dipole moment | 4.10 Dừa |
| Thermochemistry | |
| Std molar entropy (S⦵298) | Std molar entropy (S⦵298) of 11Α,17Α Dihydroxy-Progesterone is 607.3 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -643.2 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | Std enthalpy of combustion (ΔcH⦵298) of 11Α,17Α Dihydroxy-Progesterone: **-8379 kJ/mol** |
| Std molar entropy (S⦵298) | 241.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -623.5 kJ/mol |
| Pharmacology | |
| ATC code | G03DA03 |
| ATC code | G03DA03 |
| Hazards | |
| Main hazards | May cause respiratory irritation. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | H360, H362 |
| Signal word | Warning |
| Hazard statements | H315, H319, H335 |
| Precautionary statements | P210, P261, P264, P270, P280, P301+P312, P302+P352, P304+P340, P305+P351+P338, P312, P330, P337+P313, P363, P403+P233, P501 |
| NFPA 704 (fire diamond) | 1-1-1-0 |
| Flash point | Flash point: 9 °C |
| Lethal dose or concentration | LD50 (rat, oral): >1000 mg/kg |
| LD50 (median dose) | LD50: 3100 mg/kg (oral, rat) |
| PEL (Permissible) | PEL (Permissible) of 11Α,17Α Dihydroxy-Progesterone: Not established |
| REL (Recommended) | 0.2-0.5 mg/day |
| Main hazards | May cause cancer. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | `GHS06, GHS08` |
| Signal word | Warning |
| Hazard statements | H315, H319, H335 |
| Precautionary statements | P210, P261, P264, P280, P301+P312, P302+P352, P305+P351+P338, P308+P313, P405, P501 |
| NFPA 704 (fire diamond) | NFPA 704: 2-1-0 |
| Flash point | > Flash point: 291.1 °C |
| LD50 (median dose) | LD50: 894 mg/kg (Rat, subcutaneous) |
| NIOSH | BV9O39G071 |
| PEL (Permissible) | PEL (Permissible) = Not established |
| REL (Recommended) | 0.0025-0.01 mg/kg |
| Related compounds | |
| Related compounds |
11-Ketoprogesterone
Cortisone Hydrocortisone Corticosterone 11β-Hydroxyprogesterone |
| Related compounds |
11α-Hydroxyprogesterone
17α-Hydroxyprogesterone Cortisone Hydrocortisone |
Providing high-quality chemical products and logistics solutions for global trade partners.
